Become A Wiser, More Profitable Investor

📈   Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments - Seeking Alpha

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company specializing in developing treatments for central nervous system [CNS] conditions. The company has two successful FDA-approved commercial franchises, Nuplazid (pimavanserin), approved in 2016 for Parkinson’s disease psychosis, and Daybue (trofinetide), approved in March 2023 for Rett syndrome. Despite a setback with a failed clinical trial for a new indication for Nuplazid as a treatment for schizophrenia, the company stands strong with solid sales revenue for its commercial products and the advancement of its investigational pipeline. Hence, I rate the stock a “buy” for investors looking for steady value accumulation in biotech.

seekingalpha.com     Jun 06, 2024